Retail-Grade Engagement for Modern Life Sciences
Retail has long been a testing ground for digital innovation — from omnichannel experiences to hyper-personalization and artificial intelligence (AI)-driven commerce. With increasing consumerization in healthcare, life sciences leaders are taking a page from the retail playbook to reimagine how they engage patients, providers and partners in the health ecosystem.
Here we pull insights from our three-part series “The Retail Race,” developed in partnership with commercetools, to explore what life sciences can learn from retail’s transformation. EPAM’s Howard Allen, VP, Life Sciences, Digital Solutions, and David George, Managing Principal, Life Sciences Consulting, detail how omnichannel strategies, personalization and AI are shaping the industry’s engagement strategies for the better.
The Omnichannel Imperative
Uniting Fragmented Journeys in Pharma Commerce
As the retail world embraces omnichannel experiences that blend digital and physical touchpoints, life sciences companies face a parallel challenge: how to connect with diverse stakeholders across complex ecosystems. “In the pharmaceutical business, the person who makes the decision to use the product is a healthcare practitioner,” David George explains, “and the way you reach out to them is very different from how you reach out to the patient.” Add regulators, distributors and hospital procurement teams to the mix, and it’s easy to see why pharma engagement remains fragmented. Each audience requires its own strategy — and today, most organizations still manage them through siloed platforms and tools that can’t deliver a unified experience.
A multichannel world hinges on a centralized tech backbone — one that unifies data, experience and operations. For pharmaceutical companies, that means evolving beyond legacy systems and point solutions and moving toward modern, composable and compliant infrastructures. “Omnichannel, at least in theory, is about a joined-up journey for patients or for healthcare practitioners,” George notes. “But the reality is those journeys are not joined up yet.”
Many organizations are beginning to address this gap through modular content strategies, which make it possible to reuse, localize and distribute materials efficiently without re-entering lengthy medical, legal and regulatory (MLR) cycles. The result is not just operational efficiency but greater message consistency and faster speed to market across brands, regions and therapeutic areas.
Personalization Beyond the Product
Adapting the Ecosystem View
In retail, personalization has become the battleground for customer loyalty — where composable commerce enables brands to deliver experiences that feel tailored, responsive and uniquely “theirs.” Life sciences companies are at a similar inflection point. George shares, “If you really want to do personalized journeys for patients, pharmaceutical and MedTech companies need to start thinking outside the silo of their contribution to that journey.” That means looking beyond the single prescription or device and understanding the broader treatment pathway. Patients managing chronic conditions like diabetes don’t just take one drug; they experience a continuum of interactions across care teams, therapies and support programs. To be relevant, life sciences organizations must personalize for the whole journey, not just their own role within it.
Composability Catalyzes Connection
Traditional systems were never designed for this kind of dynamic personalization. Just as legacy commerce platforms can’t handle today’s need for flexibility and speed, monolithic customer relationship management (CRM) and content systems in pharma often trap valuable insights in silos. Composable architectures — modular, API-driven ecosystems — are changing that. By decoupling capabilities, life sciences companies can build adaptive experiences that evolve with each stakeholder’s context. Whether it’s integrating real-time data from connected devices, surfacing relevant content to a healthcare provider (HCP) based on their specialty or tailoring education to a patient’s stage in therapy, composability enables responsiveness without sacrificing compliance or consistency.
Balancing Automation with the Human Touch
Despite the excitement around AI and automation, personalization in healthcare will never be purely algorithmic. Trust still matters — between physician and manufacturer, between patient and brand. “You’re not going to like a chatbot the way you like a person,” says George. The next evolution of life sciences engagement will come from blending human empathy with digital efficiency — designing CRMs and experience platforms that can seamlessly shift between automated and human-led interactions. By striking that balance — and ensuring every message is contextually relevant, empathetic and grounded in real clinical value — organizations can build trust while scaling personalization across every channel and audience.
AI’s Influence
Harnessing the Data Boom
After years of building modern digital platforms and tailoring experiences for patients, providers and researchers, the industry now finds itself sitting on an unprecedented volume of data. The focus has moved beyond simply digitizing operations and creating data representative of each stakeholder in the care ecosystem to harnessing said data to fuel insight, innovation and measurable outcomes. Here’s looking at you, AI.
But AI use cases have come to mean very little without a supporting business case. Says Howard Allen, “Our clients have moved from ‘where could we use GenAI?’ to ‘where are we going to get value from using GenAI?’” Early wins are emerging across areas like patient support, intelligent content search and workflow automation — features that improve speed and precision without risking compliance. Just as retail has used AI to deepen customer engagement, pharma is finding value in small, measured steps that build organizational confidence and readiness for larger-scale transformation.
Building the Infrastructure for Intelligent Growth
If you ask our data scientists, the true transformation lies in being AI-ready — ensuring that systems, data and governance frameworks are structured to enable scalable, compliant innovation. Composable platforms and well-governed data ecosystems form the foundation, while tailored AI engines (such as those built to control and qualify data for life sciences contexts) make it possible to apply intelligence safely and effectively. As pilots graduate to enterprise-grade AI initiatives, success will hinge on how well companies align human expertise, ethical oversight and intelligent automation to accelerate value creation. Just as in retail, those who center their AI strategies on the human experience — whether patient, clinician or scientist — will be the ones who move further, faster.
So, retail-focused life sciences leader — what’s your next move? Start by breaking down silos between commercial, clinical and patient-facing functions. Invest in composable architectures that make it easier to pilot and scale new capabilities (from modular content to AI-powered personalization). Most importantly, embed experimentation into the culture: test, measure and iterate to understand where digital can drive real clinical and commercial impact. Just as retailers evolved from channels to ecosystems, life sciences organizations that build connected, insight-led experiences today will be the ones shaping the intelligent healthcare landscape of tomorrow.
Learn more about EPAM’s Life Sciences & Healthcare practice. To watch the full “Retail Race” series on YouTube featuring insights for other industries, click here.
EPAM has been recognized in Forrester’s Commerce Services Landscape, Q3 2025 report, an overview of 40 notable providers shaping the future of commerce. This recognition reflects our dedication to service excellence and client-focused solutions, backed by a strong track record of delivering impactful, large-scale commerce projects and deep industry expertise.
